Member Info for tqhussain

https://www.investorschronicle.co.uk/ideas/2023/02/09/bargain-shares-2023/

NSCI makes the list!

what news?

I was recently told business as usual (whatever that means) and company keeping a low profile when it comes to shareholder interaction.

NSCI only have a 1% holding but still looks like a great product for an important illness.

https://www.verywellhealth.com/new-screening-test-for-sepsis-7097947

https://www.youtube.com/watch?v=sRP1HeuaNL0
Found the link, go to 44 mins.

Around May-June.

In one of the webinars I recall the management saying the CE marking for the Covid test is a few weeks away but I don’t recall seeing any follow up on that.

With Covid coming back in to the headlights it would be good to know what is happening since this update in May.

ProAxsis has completed the development and validation of the AstraZeneca COVID-19 antibody test with "impressive performance evaluation results."



In June 2021 ProAxsis entered into an exclusive licensing agreement with the global biopharmaceutical company AstraZeneca, under which ProAxsis took responsibility for completing the development, validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay).

Long may it continue. PDSB finished up 13%.

PDSB doing really well today.

Overall survival = OS

Median OS is 21 months in 29 checkpoint inhibitor refractory patients who received the triple combination. The reported historical median OS in patients with CPI refractory disease is 3-4 months.
In CPI naïve subjects, 75% remain alive at a median follow-up of 27 months. As a result, median OS has not yet been reached. Historically median OS for similar patients with platinum experienced CPI naïve disease is 7-11 months.

http://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/118-2022-news/752-iotecheportsedianverallurvivalof21ont20221228

Sagetech medical also has a new website. Looks like they are ready to go commercial.

https://www.sagetechmedical.com/products-services/

Our portfolio company FOx Biosystems has been awarded €2.5 million European Innovation Council and SMEs Executive Agency (EISMEA) grant to accelerate the market introduction of unique Extracellular Vesicle (EV) analysis and isolation application.

Thomas van Elzakker, CEO of FOx Biosystems comments: “This grant is a clear validation of the urgent need for the benefits we offer to the fast-growing EV research market. It recognizes the unique potential value of our technology to obtain high quality and unbiased research data in this field, removing the current bottlenecks scientists are struggling with.''

https://www.linkedin.com/posts/sagetech-medical_sidsolutions-siddock-circulareconomy-activity-7006920583959465984-pMlc?utm_source=share&utm_medium=member_ios

Seems like a lot is going on at Sagetech.

https://www.linkedin.com/posts/carlos-jaureguizar_in-our-second-year-of-eco-disruptive-im-activity-7006679425362649089-uecq?utm_source=share&utm_medium=member_ios

https://www.linkedin.com/posts/emvcapital_constructiontech-eisinvestment-climatechangeinvestment-activity-7006664588930822144-esc-?utm_source=share&utm_medium=member_ios

Good interview by Frank (CEO PDSB).

https://tradersnewssource.com/interview-pdsb/

Our holding worth ~ £10m.

Sofant has a bright future. They are working with some key institutions like ESA. IMO, they will be a takeover target in the future.

Hopefully another 6 months for so before we get some meaningful news.

‘An expert contract lab has been commissioned to carry out troubleshooting and assay optimisation to complete the training set, which will be a significant value inflection point for the company, now expected in the first half of 2023.

· The company is exploring avenues for commercialisation and opportunities, recognising the significant value inflection points and continues to work closely with Fosun Pharma for the successful development and realisation of returns from the business.’